Differences
This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revision | Next revisionBoth sides next revision | ||
hepatocellular_carcinoma [2019/09/10 19:56] – [Current clinical risk assessment] admin | hepatocellular_carcinoma [2019/09/11 13:19] – [Current clinical risk assessment] Removed. admin | ||
---|---|---|---|
Line 60: | Line 60: | ||
- Ching, Travers, Sijia Huang, and Lana X. Garmire. "Power analysis and sample size estimation for RNA-Seq differential expression." | - Ching, Travers, Sijia Huang, and Lana X. Garmire. "Power analysis and sample size estimation for RNA-Seq differential expression." | ||
- Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma, [[http:// | - Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma, [[http:// | ||
- | |||
- | ---- | ||
- | |||
- | ===== Current clinical risk assessment ===== | ||
- | |||
- | Percent rise in AFP and the total amount of AFP (alpha feto protein) is a common risk indicator for HCC. If it rises quickly it suggests aggressive tumor. If AFP is over 500 it suggests vascular involvement or aggressiveness. If regionally ablated and recurs within three months, this is also suggestive of an aggressive tumor. Other criteria include: disease burden, CP cirrhosis, portal vein thrombosis, AFP. CLIP score and BCLC score are also used in clinic. | ||
---- | ---- |